ABHD16B

Across TCGA pan-cancer cohorts, ABHD16B RNA is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ABHD16B data layer compared with 6 for mutation status.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ABHD16B RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated ABHD16B expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

SCLC are the cancer types where ABHD16B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.773	0.412	<.001	40	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ABHD16B–SCLC (DFS)

Open the SCLC breakdown →